[Latest] Global Ultrapure Water Market Size/Share Worth USD 3,989 Million by 2033 at a 10.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
May 02, 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, May 02, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Ultrapure Water Market Size, Trends and Insights By Application (Cleaning,...
With Support from AWS, Yseop Develops a Unique Generative AI Application for Regulatory Document Generation Across BioPharma
May 02, 2024 09:00 ET
|
Yseop
Yseop, with support from Amazon Web Services (AWS), announced the development of an enhanced Generative AI application for the Biopharma industry.
New YPrime Report Highlights eCOA's Impact on CNS Trials
May 01, 2024 08:00 ET
|
Y-Prime, LLC
YPrime has released a new report, Insights into CNS Clinical Trials, which demonstrates to sponsors how eCOA can help streamline CNS research.
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies
April 30, 2024 07:00 ET
|
Replay Bio
Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies Phase 1/2...
NK Cell Therapies Pipeline Report 2024: Insights on 80+ Companies and 100+ Pipeline Drugs, Including ALECSAT (CytoVac), NKTR-214/Bempegaldesleukin (Nektar Therapeutics), and Monalizumab (Innate Pharma)
April 26, 2024 04:12 ET
|
Research and Markets
Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "NK Cell Therapies - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts
April 25, 2024 07:00 ET
|
Nucleome Therapeutics
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes Scientific Advisory Board of world-leading experts John Davis brings direct clinical expertise as...
23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 16:05 ET
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced that two...
Natural Killer (NK) Cell Therapy Pipeline Research Report 2024: Comprehensive Insights About 100+ Companies and 185+ Pipeline Drugs
April 19, 2024 07:35 ET
|
Research and Markets
Dublin, April 19, 2024 (GLOBE NEWSWIRE) -- The "Natural Killer (NK) cell therapy - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This "Natural Killer...
[Latest] Global 3D Cell Culture Market Size/Share Worth USD 4.6 Billion by 2033 at a 11.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
April 18, 2024 12:30 ET
|
Custom Market Insights
Austin, TX, USA, April 18, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “3D Cell Culture Market Size, Trends and Insights By Product (Scaffolds Based 3d...
Sezary Syndrome Pipeline Insights 2024, Featuring Major Players 4SC, Seagen, Merck Sharp & Dohme, Innate Pharma, Trillium Therapeutics and Secura Bio
April 15, 2024 10:07 ET
|
Research and Markets
Dublin, April 15, 2024 (GLOBE NEWSWIRE) -- The "Sezary Syndrome - Pipeline Insights, 2024" has been added to ResearchAndMarkets.com's offering.The report provides comprehensive insights about 5+...